Patient Involvement in the Asia Pacific – 2026 Workshop Report
This CIRS multi-stakeholder workshop examined strategies for embedding meaningful patient engagement and patient experience data in regulatory and HTA processes in the Asia-Pacific.
Good Review Practices at the Zambian Medicines Regulatory Authority
Good Review Practices (GRevPs) are an important component of regulatory systems strengthening and support progress in World Health Organization (WHO) Global Benchmarking Tool (GBT) assessment. This poster was presented [...]
From vision to reality: Two decades of progress in global drug development and regulatory innovation
Twenty years ago, participants at a CIRS workshop explored ideas that at the time appeared ambitious, including rolling reviews, facilitated regulatory pathways, collaborative assessments and real-time data sharing. Many [...]
African Medicines Agency (AMA): Origins, Evolution and Future Prospects
This poster was presented at DIA 2026 and examines the development of the African Medicines Agency (AMA), tracing its evolution from the African Medicines Regulatory Harmonisation (AMRH) Programme to its [...]
CIRS 2025 Annual Report
The CIRS 2025 Annual Report highlights a year of independent research, global stakeholder engagement and evidence-based insights aimed at advancing regulatory and health technology assessment (HTA) policies and processes. Inside [...]
CIRS R&D Briefing 105 – HTA Landscape under the EU HTA Regulation
Baseline mapping of national HTA authorities across the EU and EEA The EU Health Technology Assessment Regulation (HTAR) has moved from policy to practice, with Joint Clinical Assessments (JCAs) [...]
Comparative review of 10 HTA systems – Dai 2026
Overview Health technology assessment (HTA) plays a key role in supporting evidence-informed healthcare decision making, pricing, reimbursement, and coverage decisions worldwide. As countries seek to strengthen health policy and [...]
Q2 2026 Newsletter
We are pleased to share the latest CIRS newsletter with you, providing an update on our recent activities, research outputs, and upcoming work across medicine regulation and HTA. 🔍In [...]
CIRS RD Briefing 106 – New drug approvals by six major authorities 2016-2025
Overview This R&D Briefing presents the Centre for Innovation in Regulatory Science (CIRS) annual analysis of new active substance (NAS) approvals by six major regulatory authorities: the European Medicines [...]
Webinar on Innovative Approaches to Regulatory Reliance
Watch Webinar Recording Join us for a webinar on regulatory reliance on Tuesday 30 June 9 AM Mexico 10 AM Colombia, Ecuador, Peru, EST 11am Chile 12 PM Argentina, [...]